Our Mission & Vision
A small company delivering big solutions in neonatal preclinical models.
Neonatal research faces unique challenges: limited therapeutic options, ethical constraints, and complex physiological differences. Traditional preclinical models often fail to predict neonatal responses accurately.
Neophast bridges this gap by providing validated, ethical, and predictive neonatal models powered by artificial intelligence, enabling safer and more effective therapeutic development for our most vulnerable patients.
Revolutionary Neonatal Models
AI-Enhanced Precision
Machine learning algorithms analyse complex neonatal physiological patterns, improving predictive accuracy by 40% compared to traditional models.
Validated & Ethical
Our models undergo rigorous validation protocols whilst maintaining the highest ethical standards, ensuring reliable results without compromising patient welfare.
Translational Focus
Designed specifically for research pharmaceutical development, our models accelerate the path from laboratory discovery to clinical application in neonatal care.
Expert Leadership Team
Dr. José Martínez Orgado
Chief Scientific Officer
Leading neonatologist with over 30 years of clinical and research experience. Pioneer in neonatal neuroprotection and translational medicine at Hospital Clínico San Carlos.
Dr. Luis Arruza
Chief Technolgy Officer
Neonatologist with high clinical expertise in neonatal neurology. Expert in preclinical model development with extensive experience at Hospital Clínico San Carlos.
Dr. Merari Tumin Chevalier
Chief Executive Officer
Scientific entrepreneur. Combines technological and scientific rigour with strategic business acumen to drive innovation in medical research and development.
Partner with Neophast
Universities & Research Centres
Accelerate your neonatal research with validated models and AI-powered analytics. Access cutting-edge tools for breakthrough discoveries.
Pharmaceutical Companies
Reduce development timelines and costs with predictive neonatal models. Ensure safer, more effective therapeutics for paediatric populations.
Start Collaboration
Keep up to date with our latest news!